Uncategorized

Alto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 miss

Published

5 days ago

on

Alto Neuroscience said its PDE4 inhibitor failed a mid-stage trial in schizophrenia-related cognitive impairment, prompting the biotech to drop plans to advance the program on its own.

Alto said Wednesday it …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version